Last reviewed · How we verify

NCT05892120: App

A Smartphone App on Medication Adherence

Status unknown Last updated 7 June 2023
What this trial tests

trial testing the MedAdhere app in Medication Adherence in 100 participants. Status unknown.

Timeline
1 June 2023
Primary endpoint
25 July 2023
31 December 2023

Quick facts

Lead sponsorKaohsiung Medical University Chung-Ho Memorial Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 June 2023
Primary completion25 July 2023
Estimated completion31 December 2023
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Who can join

Adults 20 to 65, any sex, with Medication Adherence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Efficacy of a Smartphone App in Enhancing Medication Adherence and Accuracy in Individuals With Schizophrenia During the COVID-19 Pandemic: Randomized Controlled Trial.
    Chen HH, Hsu HT, Lin PC, Chen CY, et al · · 2023 · cited 12× · PMID 38096017 · DOI 10.2196/50806

Verify or expand the search:

Other recruiting trials for Medication Adherence

Currently open trials in the same condition.

Other Kaohsiung Medical University Chung-Ho Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05892120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing